Lundbeck to buy Longboard Pharma in $2.6 billion deal
Oct 14 (Reuters) - H Lundbeck A/S HLUNb.CO has agreed to buy US-based Longboard Pharmaceuticals LBPH.O in a $2.6 billion deal to boost its pipeline of treatments for neuro-rare conditions, the companies said on Monday. (Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli) ((Manas.Mishra@thomsonreuters.com; www.twitter.com/Manaswrites15;))
Recent news on H Lundbeck A/S
See all newsEurope Research Roundup: BAWAG Group, Enka Insaat, Partners Group Holding
Brief: CMS Announces Selection Of Drugs For Third Cycle Of The Medicare Drug Price Negotiation Program
Europe Research Roundup: BNP Paribas, Swedbank, Volkswagen
H Lundbeck steps down from takeover for Avadel, shares rise 3%
Brief: H Lundbeck A/S Says Noted That Our Offer For Acquiring Avadel No Longer Is Considered Superior By Their Board, We Are Currently Considering Our Options